CN109963565A - 一种药物组合物及其制备方法 - Google Patents

一种药物组合物及其制备方法 Download PDF

Info

Publication number
CN109963565A
CN109963565A CN201880004396.3A CN201880004396A CN109963565A CN 109963565 A CN109963565 A CN 109963565A CN 201880004396 A CN201880004396 A CN 201880004396A CN 109963565 A CN109963565 A CN 109963565A
Authority
CN
China
Prior art keywords
active constituent
carrier material
pharmaceutical preparation
solid
solid dispersions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004396.3A
Other languages
English (en)
Other versions
CN109963565B (zh
Inventor
张代美
张婷婷
丁欢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109963565A publication Critical patent/CN109963565A/zh
Application granted granted Critical
Publication of CN109963565B publication Critical patent/CN109963565B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种固体分散体、其制备方法以及包含该固体分散体的固体制剂。所述固体分散体含有(R)‑4‑氨基‑1‑(1‑(丁‑2‑炔酰基)吡咯烷‑3‑基)‑3‑(4‑(2,6‑二氟苯氧基)苯基)‑1,6‑二氢‑7H‑吡咯并[2,3‑d]哒嗪‑7‑酮或其可药用盐和载体材料，所述载体材料选自醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880004396.3A 2017-07-04 2018-07-03 一种药物组合物及其制备方法 Active CN109963565B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017105367059 2017-07-04
CN201710536705 2017-07-04
CN2017111050756 2017-11-10
CN201711105075 2017-11-10
PCT/CN2018/094211 WO2019007317A1 (zh) 2017-07-04 2018-07-03 一种药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN109963565A true CN109963565A (zh) 2019-07-02
CN109963565B CN109963565B (zh) 2021-09-03

Family

ID=64950432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004396.3A Active CN109963565B (zh) 2017-07-04 2018-07-03 一种药物组合物及其制备方法

Country Status (13)

Country Link
US (1) US11304945B2 (zh)
EP (1) EP3650025A4 (zh)
JP (1) JP7190452B2 (zh)
KR (1) KR20200024237A (zh)
CN (1) CN109963565B (zh)
AU (1) AU2018296476B2 (zh)
BR (1) BR112019027473A2 (zh)
CA (1) CA3066046A1 (zh)
MX (1) MX2019015612A (zh)
RU (1) RU2767872C2 (zh)
UA (1) UA127413C2 (zh)
WO (1) WO2019007317A1 (zh)
ZA (1) ZA201908090B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
EP3977997A4 (en) * 2019-05-31 2022-07-27 Jiangsu Hengrui Medicine Co., Ltd. SOLID DISPERSION AND PROCESS FOR PRODUCTION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
WO2016145138A1 (en) * 2015-03-10 2016-09-15 Shionogi Inc. Solid dispersions
CN106573002A (zh) * 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080061354A (ko) * 2005-08-29 2008-07-02 사노피-아벤티스 유.에스. 엘엘씨 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
KR20200017549A (ko) 2012-06-04 2020-02-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
JP6192244B2 (ja) * 2013-01-22 2017-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改良されたバイオアベイラビリティを有する薬学的組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
CN106573002A (zh) * 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
WO2016145138A1 (en) * 2015-03-10 2016-09-15 Shionogi Inc. Solid dispersions

Also Published As

Publication number Publication date
TW201906609A (zh) 2019-02-16
US11304945B2 (en) 2022-04-19
RU2020102280A3 (zh) 2021-09-17
EP3650025A1 (en) 2020-05-13
UA127413C2 (uk) 2023-08-16
BR112019027473A2 (pt) 2020-07-07
AU2018296476A1 (en) 2020-01-16
KR20200024237A (ko) 2020-03-06
ZA201908090B (en) 2021-08-25
WO2019007317A1 (zh) 2019-01-10
AU2018296476B2 (en) 2023-11-02
CA3066046A1 (en) 2019-01-10
RU2767872C2 (ru) 2022-03-22
US20200171031A1 (en) 2020-06-04
CN109963565B (zh) 2021-09-03
RU2020102280A (ru) 2021-08-04
EP3650025A4 (en) 2021-04-28
MX2019015612A (es) 2020-02-26
JP7190452B2 (ja) 2022-12-15
JP2020525415A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
AU2019246824B2 (en) Pharmaceutical compositions of therapeutically active compounds and their methods of use
JP6756617B2 (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
KR101737250B1 (ko) 개선된 생체이용률을 갖는 약학 조성물
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
CN108884080B (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
JP7437460B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
CN109963565A (zh) 一种药物组合物及其制备方法
CN104540822B (zh) 达拉菲尼甲磺酸盐的晶型及其制备方法
KR20210089210A (ko) 실질적 비정질인 메조포러스 탄산마그네슘을 포함하는 신규한 비정질 활성 제약 성분
CN112933049B (zh) 含无定型态芳杂环化合物的组合物、其制备方法及用途
US20080014263A1 (en) Amorphous eprosartan mesylate and process for the preparation thereof
CN107405350A (zh) 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物
TWI837095B (zh) 一種醫藥組成物及其製備方法
JP6767382B2 (ja) トピロキソスタットの新規結晶形及びその製造方法
RU2816913C2 (ru) Твердая дисперсия и способ ее получения
BR102012027409B1 (pt) composição farmacêutica e seu método de preparo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009389

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant